You are here

Primary tabs

InSitu Biologics


Invest in Anestagel. A new, opioid-free painkiller.

InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. AnestaGel may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernia, and more. For an in-depth look at our plans, audited financials, and other company information please read our Regulation A+ offering circular qualified by the U.S. Securities and Exchange Commission (SEC).

On average, 115 Americans die every day from an opioid overdose.

Recent Videos

Morgan - Medical Device Sales

Jeff - Medical Device Investor

Max - Fire Mitigation Worker

Insitu Biologics

Why AnestaGel

Why We Created AnestaGel

We identified the opportunity to make a better sustained release pain drug after we eluted colored water for over seven days from our Matrix™ BioHydrogel. After we did that, we knew we could pursue the perfect site specific, sustained release product for regional pain relief. AnestaGel could stay in place, elute for days, and hold a larger, non-toxic dose of the non-opiate drug, bupivacaine. We surveyed numerous physicians, and the overwhelming response to what we were doing confirmed our own beliefs: AnestaGel is what surgeons and anesthesiologists want for a post-operative analgesic.

Pain Management


According to The New Guidelines Released for Postoperative Pain Management, by Dr. Laurie Barclay and Pauline Anderson, acute postoperative pain is common, occurring in more than 80% of patients, with approximately 75% of these having moderate, severe, or extreme pain. Postoperative pain relief is inadequate in more than half of patients, which can negatively affect quality of life, function, and functional recovery, as well as increasing the risks for postsurgical complications and persistent postsurgical pain. Complications due to catheter placement for pain pumps, and patients self-medicating with opiates is not the answer. A site specific sustained release non-opiate drug, that lasts for at least 72 hours, with quick onset to get ahead of the pain curve and keep the nerve receptors disengaged is the answer.

Chronic Pain:


million Americans
suffer from chronic pain each year

Economic Impact:

$635 billion

The annual economic impact of pain in the U.S. is estimated to exceed $635 billion affecting more lives
than heart disease, diabetes and cancer combined.

Opioid Epidemic


Although opioids prove to be an effective treatment for pain management, the issues associated with opioid addiction continue to garner major focus. The need for a more effective, longer-lasting product for post-operative pain management is critical, and represents a significant positive behind the early commercial acceptance and success of Exparel®, despite its shortcomings, and in the development of, AnestaGel, which could be an effective non-opioid alternative in controlling surgical pain. Getting ahead of the pain curve and staying ahead of the pain curve for 72 hours is the key to reducing opioid use, especially in children, effectively eliminating the triggering of the opioid receptor.

Opioid Facts / Stats

  • 1

    Opiates were declared an epidemic by the Centers for Disease Control

  • 2

    Over 64,000 deaths were reported in 2016 due to drug overdoses.

  • 3

    On average, 115 Americans die every day from an opioid overdose.

  • 4

    40% of all opioid overdose deaths involve a prescription opioid.

  • 5

    Each year more than 70 million postsurgical patients receive opioids, and research shows 1 in 15 will go on to long-term use

  • 6

    In the U. S. there is a 55% increase in length of hospital stay due to opioid related AEs

  • 7

    A CDC study shows that even one-day prescriptions can lead to long-term abuse, and a full 30% of those given a month-long prescription developed opioid dependence.

What is AnestaGel

AnestaGel is a biocompatible drug, the consistency of gelatin, that is being explored for the use as injectable or spread by a surgeons hand and instruments into the target area of the body that would create post-surgical pain. AnestaGel then targets and binds to pain receptors so that patients could have near immediate pain-relief while lasting up to three days, or more. Unlike almost all other painkillers, AnestaGel is targeted for a specific region within the body, is designed to stay in that area, does not migrate to other regions of the body, and is easily metabolized* (*findings based on pre-clincial trials).

AnestaGel vs Opioids


  • Non-addictive
  • Site-specific
  • Fast-acting
  • Analgesic effect for 72+ hours


  • Used in 80% of all procedures
  • Highly Addictive
  • Short-acting (hours)
  • Central Nervous System & Cardiovascular toxicity
  • Cognitive disorientation, slow breathing, sedation, and other side effects
  • Non site-specific
  • Outcome unsure

AnestaGel Medical Specialties




Oral Surgery

Plastic Surgery

Current Treatments


The current post-operative pain treatment options is dominated by opiates at 95% use and then other non-opioids make up 5%. Only one sustained release drug for post-operative has been cleared by the FDA. That drug is Exparel. While it does work, many clincal shortcomings have been reported in peer-reviewed, published journal articles. Based on our pre-clinical reports and surveying, we believe AnestaGel represents the product everyone wants, with the potential outcomes they expect from a sustained release drug.

AnestaGel vs. Industry

AnestaGel™ offers a new and transformational approach to perioperative pain management
that is opioid-sparing, tunable, biocompatible, target site-specific, and flexible

Swipe left to view table


Design Set Pumps Exparel AnestaGel




Removable / Reversible (if necessary








pH Neutral




Predictable Elution












Absorbed / Metabolized




Single Step Use




Pre-Clinical GLP Study

Under the direction of Dr. Jake Hutchins, we compared AnestaGel™ to EXPAREL (Pacira, Inc.) in a GLP controlled pre-clinical study. Jake is the Director of the Regional Anesthesia Acute Pain and Ambulatory Surgery Division, and the Medical Director for the M Health Ambulatory Surgery Center, at the University of Minnesota. We found that:

300% Longer

Initial animal study revealed AnestaGel lasted up to 300% longer

8x More Capacity

AnestaGel carried 8 times more capacity


AnestaGel had full nerve block beyond 72 hours

Information about the pre-clinical results can be found in the Offering Circular
Or see our study at the Journal of Pain Research

Market Size

Insitu Biologics believes that AnestaGel can be in three distinct markets for perioperative
pain management

Surgical Site / Perioperative

Estimated 90 million surgical procedures in the US, resulting in $10B of drugs / devices being sold in the US

Peripheral Nerve Block

This occurs in the majority of surgical procedures, and is a product market that is estimated to grow to $20B by the Year 2025


Estimated 2.5M procedures in the US and a product market estimated at $1B

Animal Market

InSitu Biologics intends to pursue a strategic licensing transaction with a worldwide Animal Care Company that it believes could be of significant financial benefit to the Company. The global pet care market is expected to reach USD 202.6 billion by 2025, according to a new report by Grand View Research, Inc. Rise in the adoption of pets and growing demand for premium care products, and veterinarian care are a few factors expected to drive market growth.


For 2018 reports, find M&A Activity, Capital Market Conditions, and Current Trends for the Pet Industry over at The Deal Hound

Watch our recorded veterinarian webcast

Animal Market Opportunity - AniGel SR

We believe that AniGel SR, composed of our Matrix Technology and our proprietary mix of bupivacaine, could be brought to the rapidly expanding $200B+ annual Worldwide Animal Health market in the very near future by the right commercial partner. A few examples of those surgical procedures include:

The combined surgical market for the three segments above represents over 50,000,000 surgeries annually, at a projected ASAP of $75- $100 for Canine and Feline, and $275 for Equine.

In just two years, an estimated 14,000 of the 98,000 veterinarians in the US have been trained on the use of Nocita, an analgesic extending liposome injection. AniGel has soundly outperformed Nocita in head to head tests measuring pain relief and the level of non-toxic pain relief medicine in the bloodstream.

The Opportunity


Pre-Offering Valuation


Current Share Price


Max Capital Raise


Min Investment

“ As a high volume surgeon I use EXPAREL all of the time; but as a user, we know its performance varies from patient to patient. When I saw the work that was being done on Matrix BioHydrogel, I had to get involved. AnestaGel™ is the product I wanted from the start. That’s why I am a shareholder. ”

-Dr. Stefano Sinicropi Spine Surgeon, President, Midwest Spine and Brain Institute

Market Cap

Market cap compared to leading competitors

As of March 21, 2019 at 11:25AM PST


What's Next?

It is very rare that an early stage financial opportunity in an easy to understand product is presented for investment to the general public. While complex in its design, and intricate to make, we believe AnestaGel represents that rare case for a potentially large return on investment, due to our low market capitalization in a large cap market. Our patent position and refinement of product components represent years of research and development being captured to bring AnestaGel to the market. Clinicians and surgeons across the country are preparing to change how they treat pain; AnestaGel is aiming to be in their repertoire of opioid alternatives as this change, which will take decades, begins.

  • 1 Create an account Start Investment
  • 2 Choose your investing method and fund your account
  • 3 Receive your shares and monitor your investment

Investing Methods

ACH / Check / Wire

Fund your investment with an ACH, check, or wire transfer.


Fund your investment with an IRA or self-directed 401k. Click the Equity Institutional image below to learn more about funding with your IRA


Meet the InSitu Biologics Executive Team

Jim has been the founder, inventor, investor, and owner operator in many med-tech ventures. Jim began working on the Matrix technology in 2007 and co-founded InSitu Biologics in 2014. Jim is an inventor on over 40 issued patents for medical products, and specializes in the total enterprise of bringing proprietary products from “just an idea” through design, scaled up manufacturing, and “to the patient”. Jim earned his Bachelor of Science from Carroll University in Waukesha, Wisconsin and his MBA from Cardinal Stritch University in Milwaukee.

James Segermark CEO

Bill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, and has been awarded over $900k in government research grants, and authored industry papers in chemical remediation and demilitarization utilizing biological systems. Bill has his Bachelor of Science from the University of Minnesota with a double major in Chemical Engineering and Biology.

Bill Taylor Chief Scientist


What is AnestaGel?

AnestaGel is a pre-clinical phase pain relief drug that consists of bupivicaine, a surgical strength “caine” medication like novacaine or lidocaine, that is released over 72-96 hours via our Matrix BioHydrogel. The Matrix is a biocompatible gel that is slowly metabolozed by the body, as the drug numbs the surrounds the tissues and nerves.

How does AnestaGel work?

AnestaGel can be injected in to tissues or smeared on the surgical site. As the Matrix absorbs water from the body tissues, the bupivacaine spreads in to the area, numbing it for days and days.

Does AnestaGel stay in place?

AnestaGel is placed on the tissue at the surgical site and does not migrate to other parts of the body.

What do your issued patents or patent applications cover?

We have over 25 US patents issued on the base material, uses and applications. That inventory can be found on the Manhattan Street Capital website by downloading the SEC Offering Circular. Recently we have had more publications on ranges of formulation, as well as delivery and field of use. We do not put any value on patent applications until they are issued nor do we discuss the content of patent applications publicly.

Does AnestaGel enter my bloodstream or restrict bloodflow?

AnestaGel is placed on the tissue at the surgical site, and only the drug that is in the Matrix BioHydrogel works its way in to the bloodstream to relieve pain.

Could AnestaGel be used in dental surgery in the future?

We do believe that our AnestaGel product could prove to be a very useful tool in the Oral Surgery space. We expect to begin our Phase 1 Clinical Study in Q1 2020. That study is to prove that AnestaGel is either safe or not for further study in people. After that, numerous uses, including Oral Surgery procedures, could be studied for efficacy in those surgeries.

Why Reg A+ and not VC or other type of venture funding?

Our Founders, and First Investor that invested $1 million, all have bought Common shares that have no liquidity preference. They are not registered either, so they cannot sell them. We did give the $1 million investor two votes for each share; that is the only difference. Venture Capital investors try to negotiate preferences and guarantees that other shareholders do not get. We are not going to do that for numerous reasons. The risk and reward is the same for everyone in our RegA+ Offering, with the difference being the more risk you are willing to take, the earlier you invest and hopefully you might pay a lower share price.

Why do we think we will be successful?

In head to head pre-clinical studies against the only product cleared for regional post-surgical pain treatment, Exparel, Anestagel provided statistically significant more pain relief than Exparel. Other studies also confirm more presence of AnestaGel in the bloodstream when compared to Exparel from 1-96 hours.

What is InSitu Biologics business model?

We operate a low overhead, fast-moving research and development company, with an eye toward monetizing the development through divesture after we have mitigated risk for the buyer(s) and increased value for our shareholders.

What exactly is this investment opportunity?

This investment goes directly to our company to pay for the completion of studies and manufacturing to get to the second phase of human studies for the FDA. Our RegA+ Offering gives people a chance to buy shares at a valuation that starts off at $24 million. Comparably, Pacira, the company that only consists of selling Exparel, is valued at nearly $2 billion dollars.

I made an investment, now what?

Upon making a successful investment, you will receive a letter from Computershare, via the US mail, after the current Tier closes. Please allow several weeks before your shares are available. Your shares are held electronically with our Transfer Agent, Computershare. You may then set up an online account with Computershare and download your subscription agreement for your records at any time. This is also proof of ownership. Please note, The Company does not issue certificates. Should something happen that does not allow you to make a successful investment, you will receive your money back.

I am outside of the US, what is the best way to fund my investment?

ACH cannot be used for international investors. Thus international investors have the option of using a wire transfer to secure their investment.

I am not an “accredited investor”, can I still invest?

Yes, Regulation A+ allows any investor (accredited or non-accredited), to invest in private companies.

How can I sell my shares? Is there aftermarket for doing that?

There currently is not a secondary market for the shares. The company believes it might pursue a listing after we have raised our money and completed the first human clinical study. At the earliest that would be in Q3 of 2019.

Risks & Disclosures

All trademarks are the property of their respective owners

New chemical entities derived from our Matrix BioHydrogel Program, which is in the early stages of development, may require more time and resources for development, testing and regulatory clearance, and may not result in viable commercial products.

Early indications of activity from GLP Pre-clinical (animal) studies of AnestaGel™ may not predict the results of clinical (human) trials

Clinical trial safety results, including for AnestaGel, may not be confirmed

Regulatory action or failure to obtain product approvals could delay or limit development and commercialization of our product candidates and result in failure to achieve anticipated revenues

We may depend to a large extent on third-party collaborators, and we have limited or no control over the development, sales, distribution and disclosure for our pharmaceutical product candidates which are the subject of third-party collaborative or license agreements

Cancellation of collaborations regarding our product candidates may impact our revenues and adversely affect potential economic benefits

Our revenues may depend on collaboration agreements with other companies. These agreements may subject us to obligations which must be fulfilled and also make our revenues dependent on the performance of such third parties. If we are unable to meet our obligations or manage our relationships with our collaborators under these agreements or enter into additional collaboration agreements or if our existing collaborations are terminated, our revenues may decrease. Acquisitions of our collaborators can be disruptive

Our cash flows are likely to differ from our reported revenues

Our revenues may also depend on milestone payments based on achievements by our third-party collaborators. Failure of such collaborators to attain such milestones would result in our not receiving additional revenues

Our business strategy includes the entry into additional collaborative agreements. We may not be able to enter into additional collaborative agreements or may not be able to negotiate commercially acceptable terms for these agreements

We will require and may have difficulty raising needed capital in the future

Offering Circular

Please read the offering circular here: Get Offering Circular

An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement, which only means that the company may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement from the here.
You should read the offering circular before making any investment.

The offering materials may contain forward-looking statements and information relating to, among other things, Insitu Biologics, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify and constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Securities are offered through Sageworks Capital, LLC., a registered broker-dealer and member FINRA/SIPC. Neither InSitu Biologics, Inc. nor Sageworks Capital, LLC provides any investment advice or make any investment recommendations to any persons, ever, and no communication through this website or in any other medium should be construed as such.  

InSitu Biologics, Inc. securities are not publicly traded and are intended for investors who do not need a liquid investment. This investment is NOT a bank deposit (and thus NOT insured by the FDIC or by any other federal governmental agency), are NOT guaranteed by Sageworks Capital, LLC or InSitu Biologics, Inc., and MAY lose value. Investors must be able to afford the loss of their entire investment. 
Any financial projections or returns shown on the website are illustrative examples only, and there can be no assurance that any valuations provided are accurate or in agreement with market or industry valuations. Investors should conduct their own due diligence, not rely on the financial assumptions or estimates displayed on this website, and are encouraged to consult with a financial advisor, attorney, accountant, and any other professional that can help you to understand and assess the risks associated with any investment opportunity. Please refer to the offering circular for full details and disclosures, including a subscription agreement should you choose to invest.

Insitu Biologics, Inc. is required to pay an advisory retainer fee of $6,000, plus the same value of warrants at the respective issue price. In addition, they will pay a technology admin and service fee of $25 per investor, plus the same value of warrants at the respective issue price. As of 11/30/2018 Insitu Biologics has paid $24,000 in fees.